An accumulating body of data in human systems has suggested the importance of improving viral vector design via tropism-modification maneuvers. [1] [2] [3] In the first instance, the demonstration of vector-associated toxicities has highlighted the deleterious effects of gene delivery to ectopic sites. On this basis, cell-specific vector-mediated transduction would, theoretically, circumvent this issue. As well, basic vector efficiencies may be suboptimal if subservient exclusively to native viral receptor limits. Thus, infectivity-enhanced vectors could also have improved potency, thus potentially allowing the achievement of a more useful therapeutic index. Clearly, the need for vector targeting is one of the most unambiguous lessons to derive from human clinical trials endeavored heretofore.
Fundamental to any attempts to retarget viruses is a basic understanding of the native determinants of their tropism. Thus, retargeting of retroviral vectors via envelope engineering strategies was based on a highly characterized understanding of the molecular basis of retroviral infection. In a similar manner, the advances in retargeting adenoviral vectors have been firmly grounded in basic virology and cell biology understandings of the relevant processes. In this regard, tropism-modification strategies based on genetic capsid modification have derived from contemporary revelations regarding key structural features of the capsid proteins. Likewise, molecular complex-based retargeting schemes for adenovirus (Ad) vectors have capitalized on the delineation of Ad entry as a two-step process, whereby internalization could be uncoupled from binding. Indeed, the needs of vector development have often been the key catalyst for the definition of relevant biology pursuant to vector design.
Of additional importance in this regard is an understanding of the determinants of vector efficacy at a 'supra-cellular' level. Further, the use of the most relevant substrate systems is likewise of importance. Given these considerations, the development of adenovirusbased vector approaches, and their rapid translation into the clinical context, has provided an object lesson. In this regard, significant disparities in vector efficacy have been noted with respect to immortalized cell lines and their cellular primary counterparts. [4] [5] [6] These disparities have been more prominent in the context of direct in vivo delivery schemes, where end-organ Ad resistance has undermined a variety of gene therapy approaches. On this basis the most complete and unambiguous understanding of the cellular determinants of Ad entry is key to the design of vectors with improved characteristics for gene therapy applications.
The current issue of Gene Therapy contains two articles of pivotal relevance to such endeavors. McDonald et al clarify the cellular determinants of Ad entry. 7 In this regard, the identification of the coxsackie and adenovirus receptor (CAR) as a major cellular factor predicating adenoviral tropism has had a major impact on understanding the biology of Ad vectors. 8 However, other reports have suggested that other cellular factors could potentially serve as primary Ad receptors and thus potentially influence overall tropism. 9 One such report has implicated the major histocompatibility complex (MHC) heavy chain as a candidate tropism determinant. To clarify this issue, the authors of this report demonstrate discordance between MHC class I heavy chain levels and Ad susceptibility. Further, heterologous expression of the MHC class heavy chain gene did not induce Ad susceptibility. Whereas these studies were carried out employing cellular binding of recombinant knob as an index of tropism, in the aggregate, this article clarifies the pre-eminent role of CAR as the dictat of Ad tropism. Thus, if other factors cooperate to allow Ad binding, their functional significance is not relevant in the context of overall Ad tropism.
The paper by Fechner et al evaluates tropism issues in the context of in vivo delivery. 10 Of note, many groups have endeavored to alter adenoviral tropism specifically for the purpose of allowing cell-specific gene delivery after systemic vascular administration. Such an endeavor assumes free Ad egress from the vascular bed to the target parenchyma cells. Studies presented within this work characterize CAR levels within various organs. The authors find a remarkable consistency across species barriers in the relative CAR levels characterizing each organ. Of note, however, in vivo gene delivery with Ad vectors did not precisely correlate with CAR levels. Thus, other factors, such as vascular egress, may play a key role in contributing to tropism in a systemic delivery context. The authors hypothesize that this may be a major factor in the high level of liver tropism exhibited by Ad vectors delivered via the vascular circuit. Clearly, this very basic aspect of vascular pharmacodynamics has not, until now, been clearly linked to the utility potentials of this vector in the context of gene therapy paradigms presuming in vivo gene delivery retargeting.
The benefits of viral vectors have been clearly delineated in a host of recent publications. 11 For Ad vectors, these have been especially apparent. In this context, the means to address Ad-refractory cells by virtue of 'CAR-independent' delivery schemes has been accomplished. [4] [5] [6] The means to achieve cell-specific gene delivery via Ad vectors has also been achieved by a variety of schemes. 12 Direct practical testing of these 'enhanced potency' vectors will occur shortly in the context of human clinical trials. These advances, however, must necessarily be understood to accrue to a limited subset of delivery paradigms. For the achievement of these same ends, subsequent to systemic vector administration, additional progress must be made with respect to understanding the dictates of Ad tropism. Advances in improving Ad vector dynamics by virtue of tropism engineering have been based upon a full understanding of the tropism determinants at the cellular level. Progress in the utilization of the vectors in vivo must be similarly based upon a more complete understanding of the determinants of tropism at the whole organism level of resolution. The current set of studies by McDonald and Fechner represent significant first steps towards the most important goal. 
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